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1. Introduction
Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic plasma
cell dyscrasia, present in 3.2% of white people over 50 years of age [1], which converts to
multiple myeloma (MM) or related disorders at a rate of just 1% a year [2], an incurable
malignancy of plasma cells. While MM is the prototypical monoclonal gammopathy, the most
common is MGUS [3].
Monoclonal  gammopathies are a  heterogeneous group of  disorders characterized by the
stable or progressive proliferation of an abnormal clone of plasma cells that continue pro‐
ducing antibodies [4]. But because these immunoglobulin proteins are abnormal and mon‐
oclonal  (identical  copies  of  each  other),  these  offer  no  protection  against  infections  and
can damage the kidney. This monoclonal immunoglobulin is called M-protein. Each basic
unit  is  a  monomeric  immunoglobulin  consisting of  two heavy chains  of  the  same class
and subclass and two light chains of the same type. The heavy chain classes are G, A, M,
D,  E (gamma,  alpha,  mu,  delta,  epsilon),  while  the light  chain types are  kappa (κ)  and
lambda (λ).
Monoclonal gammopathies are recognized on serum protein electrophoresis demonstrating a
band of migration in the beta or gamma region [5]. When a band is seen on serum protein
electrophoresis, immunofixation electrophoresis should be performed. Immunofixation
electrophoresis is the gold standard and should be performed to confirm the presence of an
M-protein and to distinguish its heavy chain and light chain type [6].
In 1952, Waldeström [7] initially reported finding an M-protein without evidence of malignant
disorder, and named the condition “essential hypergammaglobulinemia”. For some time, this
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condition was also referred to as “benign monoclonal gammopathy”. However, Kyle recog‐
nized that some patients with MGUS could progress to MM, Waldeström macroglobulinemia,
light chain amyloidosis, or related disorders. Thus, Kyle coined the term MGUS in 1978 [8]. In
2003, MGUS is defined by serum M-protein concentration less than 3 g/dL, the bone marrow
clonal plasma cell less than 10%, with no evidence of other B-cell proliferation disorders [9].
The objective of this chapter is to describe new concepts and advances concerning the diag‐
nosis, classification, management of patient, risk factors for malignant transformation and new
preventive strategies of progression of MGUS to malignant conditions.
2. Prevalence
As mentioned above, MGUS is the most common plasma cell disorders and is a potential
precursor of MM. At the Mayo Clinic during 2005, 51% of patients with a monoclonal gamm‐
opathy (n=1,510) had MGUS, 18% MM, 11% amyloidosis, 3% Waldeström macroglobulinemia
and 17% other diseases [3].
In 1972, Kyle et al [10] collected serum from 1,200 residents (≥50 y) of Thief River Falls of
Minnesota; M-proteins were detected in 15 people, 1.7% men and 0.9% women of the surveyed
population (Table 1). In 2006, Kyle et al [1] reported variability in the prevalence of MGUS
from a normal population in community practice [11, 12] or in hospitals; data was obtained
from studies carried out between 1963 and 2002. It is suggested that this variability might be
due to that some studies lacked a geographically defined population in which testing could
be performed during a specified period, and that screening methods used in many previous
studies are less sensitive than current techniques. To overcome these limitations, Kyle et al [1]
used sensitive laboratory procedures to determine the prevalence of MGUS in a large popu‐
lation (n=21,463) in a well-defined geographic area (Table 1): sample of persons aged ≥50 years
residing in Olmsted Country (Minnesota, USA). MGUS was found in 3.2% of people in their
5th decade, 5.3% in their 7th decade and 7.5% in over 85 years old (350/9469 men and 344/11,994
women) [1]. Axelsson et al [13] also reported that MGUS is more prevalent in men (1.9%) than
in women (1.3%).
The incidence in the population aged 70 years reaches 3% in Caucasian population [4] and
0.7% in Mexican mestizos [14]. The prevalence of MGUS in African Americans was 3-fold
higher than in white male veterans, among 4 million African American and white male
veterans admitted to Veterans Affairs, between 1980 and 1996 [15] (Table 1). The age-adjusted
prevalence of MGUS was 1.97-fold higher in Ghanaian men compared with white men (50-74
y) [16]. Later, they reported the risk of MGUS between white and black male United States
veterans could be associated with prior autoimmune, infectious, inflammatory, and allergic
disorders; they concluded that various types of immune-mediated conditions might act as
triggers for MM/MGUS development [17]. Recently, a disparity in the prevalence, pathogen‐
esis and progression of MGUS between blacks and whites [18] has been reported.
Multiple Myeloma - A Quick Reflection on the Fast Progress112
Site
[References]
Type Study
(Length)
Test Identify
M-protein
Nº of Persons
Studied (Age, y)
Prevalence %
(Age, y);
Incidence or
Cases
M-protein
IgG %
n/MGUS
IgA %
n/MGUS
IgM %
n/MGUS
Minnesota,
USA [10]
PB
(<1 mo)
CAE
IE
1,200 (≥50) 1.25 % (≥50)
2.8 % (≥70)
73.3 %
11/15
6.7%
1/15
20.0%
3/15
Finistere,
France [11]
Health CP
(1 y)
CAE
IE
30,279 (≥30)
17,968 (≥50)
0.2 % (all)
1.7 % (≥50)
71.7%
43/60
6.6%
4/60
21.7%
13/60
North
Carolina,
USA [12]
PB
(NA)
AGE
IFE
1,732 (≥70) 6.1% total
8.4/3.8%
blacks/whites
NA/106 NA/106 NA/106
Iceland [20] RCS
(22 y)
CAE
AGE
Population
Iceland (20-104)
11/100,000
(M)
9/100,000 (F)
55.0% 13.0% 32.0%
Hospital,
Japan [21]
HCS-BS
(16 y)
CAE
IE
6,737 (45-85) 0.93%
2.0% (≥70)
55.8% 41.6% -
Minnesota,
USA [1]
PB
(6 y)
AGE
IFE
21,463 (≥50) 3.2 % (≥50)
3.7/2.9% (M/F)
68.9%
NA/694
10.8%
NA/694
17.2%
NA/694
142 VA
hospitals
[15]
RS-IHR
(16 y)
NA 3,997,815(≥18) 0.05% total;
0.09% blacks
0.04% whites
NA/2,046 NA/2,046 NA/2,046
LHNC, Japan
[22]
RS-BS
(15.5 y)
CAE
IE
52,781 (≥42) 2.1% (all)
4.4 % (≥80)
73.6%
NA/1,088
17.7%
NA/1,088
7.5%
NA/1,088
1 hospital,
Chile [23]
RS AGE
IFE
MGUS: 17
(28-96)
NA
11/6 (M/F)
59.0%
10/17
24.0%
4/17
18.0%
3/17
Bangkok,
Thailand
[24]
SH
(6 mo)
HRGE
AGE
3,260 (50-93) 2.3%
38/46% (M/F)
64%
48/75
21.3%
16/75
--
Seongnam,
Korean [25]
KL
(1 y)
SPEP
IFE
1,118 (65-97) 3.1%
3.8/2.5% (M/F)
29%
6/21
43%
9/21
19%
4/21
Germany
[26]
PB-HNR SPEP
IFE
4,702 (45-75) 3.5%
4.4/2.7% (M/F)
59%
97/165
17%
28/165
17%
28/165
AGE: Agarose gel electrophoresis; CAE: Cellulose acetate electrophoresis; CP: Control prevalence; HCS-PS: Hospital
cohort study- atomic bomb survivors; HRGE: High-resolution gel electrophoresis; IFE: Immunofixation; IE: Immunoelec‐
trophoresis; KL: After scheduled tests for the Korean longitudinal study on health and aging; LHNC: Local hospital
Nagasaki City; M/F: Males/females; NA: No available; PB: Population based; PB-HNR: Population-based Heinz Nixdorf
Recall study; RCS: Retrospective cohort study; RS: Retrospective study; RS-BS: Retrospective study of date base of atomic
bomb survivors; RS-IHR: Retrospective study of inpatient hospitalization records; SH: Cross-sectional survey of healthy;
SPEP: Standard serum electrophoresis; VA: Veterans Affairs.
Table 1. Studies of epidemiology of MGUS
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In 2010, Wadhera and Rajkumar [19] on the basis of a systematic review of prevalence of MGUS
selected 14 of 460 articles, which met the inclusion criteria for their review [10, 12, 15, 16, 20-22]
(Table 1). They discussed study types, method sensibility and availability to detect M-protein
and diagnostic criteria. They conclude that the prevalence increases with age and is affected
by race, sex, among other factors. Further studies of prevalence are shown in Table 1 [23-26].
One long-term research studied a population-based of 1,384 patients with MGUS from the 11
counties of southeastern Minnesota who were evaluated from 1960 to 1994 [2]. These patients
were observed for a total of 11,009 person-years. Of the identified MGUS, 115 progressed to
MM or related disorders. At 10 years, 10% had progressed; 20 years, 21% had progressed; and
at 25 years, 26% had progressed. The conclusion of these authors is that the risk of progression
is about 1% per year. In 2003, a study reported that relative risk of progression was 16-fold
higher in the patients with IgM MGUS than in the white population of the Iowa Surveillance
[27]. Furthermore, risk for progression to lymphoma or a related disorder at 10 years after the
diagnosis of MGUS was 14% with an initial M-protein concentration of 0.5 g/dL or less, 26%
with 1.5 g/dL, 34% for 2.0 g/dL, and 41% for more than 2.5 g/dL [27]. Risk factors associated
with the progression will be discussed later in this chapter.
3. Diagnosis and classification of patient with MGUS
The UK Myeloma Forum and the Nordic Myeloma Study Group have proposed guidelines
for the effective clinical investigation of patients with M-proteins and management of patients
with MGUS [28]. These guidelines are almost entirely based on expert consensus opinion. They
were searched by MEDLINE and EMBASE systematically for publications from 1950 to
October 2008. They suggest that screening normal populations for M-protein for clinical
purposes are not recommended. It was suggested that serum protein electrophoresis should
be performed if there is clinical suspicion of an M-protein or when the abnormal test results
(erythrocyte sedimentation rate >30 mm/h or plasma viscosity; unexplained anemia, hyper‐
calcemia or renal failure; raised total protein/globulin or immunoglobulins; reduction of one
or more immunoglobulin class levels).
The UK Myeloma Forum and the Nordic Myeloma Study Group guidelines specifically state
that there is no evidence supporting the use of serum free light chain in monitoring patients
[28]. By contrast, the International Myeloma Working Group members suggest that serum free
light chain analysis may be a useful adjunctive test in monitoring patients with MGUS [29-33].
The ratio of κ/λ is critical to the interpretation, because an abnormal serum free light chain
ratio should only be present in the context of a plasma cell dyscrasia with severe renal failure
or other B-cell lymphoproliferative disorders [34]. It is important to note that serum free light
chain analysis by immunoassay is much more sensitive than the serum protein electrophoresis
methodology [35].
In 2010, International Myeloma Working Group has recommended a new classification of
MGUS [36]; each type must meet all the criteria set out: Non-IgM (IgG or IgA) MGUS with
serum M-protein <3 g/dL, clonal bone marrow plasma cells <10%, absence of end-organ
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damage, such as CRAB (hypercalcemia, renal insufficiency, anemia and bone lesions); IgM
MGUS with serum M-protein <3 g/dL, clonal bone marrow lymphoplasmacytic cells <10%,
absence of end-organ damage; and light chain-MGUS with abnormal free light chain ratio <0.26
or >1.65, increased level of the appropriate involved light chain, increased κ free light chain in
patients with ratio >1.65 and increased λ free light chain in patients with ratio <0.26, no
immunoglobulin heavy chain expression on immunofixation, clonal bone marrow plasma cells
<10%, and absence of end-organ damage, such as CRAB [19, 36]. Each clinical type is charac‐
terized by unique intermediate stages and progression events. The intermediate stages with
high risk of progression are [36]: (i) smoldering MM (SMM: IgG or IgA M-protein ≥3 g/dL,
and/or clonal bone marrow plasma cells ≥10%, and absence of end-organ damage, CRAB); (ii)
smoldering Waldenström macroglobulinemia (IgM M-protein ≥3 g/dL and/or clonal bone
marrow lymphoplasmacytic infiltration ≥10%, no evidence of anemia constitutional symp‐
toms); and (iii) idiopathic Bence Jones proteinuria (urinary M-protein on urine protein
electrophoresis ≥500 mg/24 h and/or clonal bone marrow plasma cells ≥10%, no immunoglo‐
bulin heavy chain expression on immunofixation, absence of end-organ damage, CRAB).
4. Risk factors for malignant transformation of MGUS
Risk factors for transformation of MGUS to malignant condition have been analyzed in several
studies. An abnormal serum free light chain ratio (κ/λ), non-IgG MGUS, and a high serum
M protein level  (≥1.5 g/dL) are three major risk factors for the progression of MGUS to
myeloma [36].
Based on the clinical markers still available, two independent studies were able to establish
predictive risk models from MGUS to MM for each clinical type of MGUS. The first model,
proposed by a group at the Mayo Clinic identifies three main risk factors for progression: serum
M-protein >1.5 g/dL, IgG subtype and normal free light chain ratio. The probability of
progression of MGUS to malignant monoclonal gammopathy is 1% per year, with an estimated
risk of progression of 34% over 20 years [37]. At 20 years of follow-up, absolute risk of
progression for MGUS patients with 0, 1, 2, and 3 risk factors are 5%, 21%, 37%, and 58%,
respectively [29].
Immunophenotyping is an attractive technique to potentially identify high levels of malignant
plasma cells among normal plasma cells [38] and for the differential diagnosis between MGUS
and MM [39]. The second model, proposed by a Spanish group, introduces a novel prognostic
criterion for MGUS. This group has established a multiparameter flow cytometry as a tool to
identify aberrant plasma cell populations: CD38+, CD19-, CD45-, CD56+ [40]. They defined two
factors: (1) a plasma cell/normal bone marrow plasma cell ratio >95% associated with higher
risk of progression, and (2) DNA aneuploidy. Free progression survival at 5 years for MGUS
patients with 0, 1, and 2 risk factors is 2%, 10%, and 46%, respectively.
Both models present advantages and disadvantages with regard to the risk stratification of
patients with MGUS [41]. The Mayo Clinical model may be useful in routine clinical practice,
but the disadvantages of the model are its poor discrimination of the risk of progression
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between groups. On the other hand, the Salamanca model is a superior model, in particular,
to identify a truly high-risk MGUS population; however, its main disadvantages are invasive‐
ness (it requires a bone marrow aspirate), technical complexity and high cost.
The biological events related to progression from normal plasma cells to MM precursor disease
and to MM involve many overlapping oncogenic steps that differently affect each individual
[42]. Several authors discuss the very early and partially overlapping molecular pathogenic
events that are shared by MGUS, and how they are associated to progression at the MGUS to
MM transition [43-45].
5. Cytogenetic studies on MGUS and SMM
MGUS, SMM and MM present common chromosomal abnormalities [46-49] whose prevalence
and relative association between these diagnostic groups have been controversial for years.
The development of new techniques and methodologies has helped to define new biomarkers
and elucidate the pathogenetic mechanisms of progression, characterized as a multistep
process from the precursor state to myeloma.
The first step in the pathogenesis is likely an abnormal response to antigenic stimulation,
mediated possibly by aberrant expression of toll-like receptors and overexpression of inter‐
leukin (IL) 6 receptors and IL-1β. This then results in the development of primary cytogenetic
abnormalities, either hyperdiploidy or immunoglobulin heavy chain translocations [36].
Hyperdiploid tumors, which include about 50% of MM tumors, often have multiple trisomies
involving chromosomes 3, 5, 7, 9, 11, 15, 19, and 21; also, a substantially lower prevalence of
immunoglobulin heavy chain translocations and monosomy of chromosome 13 compared
with nonhyperdiploid tumors. Trisomies of these same chromosomes also occur in premalig‐
nant MGUS tumors [47].
It has been well established that each translocation subgroup found in MM tumors is associated
with deregulation of a D group cyclin either directly, such as occurs with the t(11;14) (cyclin
D1) and t(6;14) (cyclin D3) or indirectly, such as occurs with the t(4;14) or in the MAF translo‐
cation group [47]. All these translocations have also been reported in MGUS (Table 2).
The first studies that showed structural chromosomal changes in MGUS and performed
fluorescence in situ hybridization experiments (FISH) found 14q32 and 13q14 abnormalities
[51, 52]. Subsequent studies have determined that approximately 50% of SMM show primary
translocations involving the immunoglobulin heavy chain locus leading to the dysregulation
of oncogenes including the Cyclin D, FGFR3/MMSET and MAF genes [46, 48, 53] (see Table
2). There is evidence of an immunoglobulin light chain-λ translocation in MGUS associated
with a prevalence of 10% in MGUS/SMM [53].
Ross et al [55] found that cases characterized by t(4;14), t(14;16), particularly the t(14;20), can
be stable as either MGUS or SMM for years before progression occurs. It has been shown
that t(4;14), t(14;16) and t(14;20) translocations are associated with a poor prognosis in MM
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(1,860 studied patients). The t(14;20) patients had a short median survival of only 14.4 months
[50].  It  has  been determined that  these  three  translocations  produce cyclin  D2 enhance‐
ment (Table 2).
Using interphase FISH, Chiecchio et al [50] performed a study to evaluate chromosome 13
deletion (delta 13), deletion of TP53 (17p13), ploidy status and immunoglobulin heavy chain
translocations. They found that 50% of MGUS patients carried one of the primary immuno‐
globulin heavy chain translocations and the remaining patients displayed a hyperdiploid
karyotype. Thus 72/189 (42%) MGUS, 70/127 (63%) SMM, and 223/338 (57%) of MM cases were
hyperdiploid. When the individual incidences of the specific translocations were compared,
only t(4;14) was significantly less frequent in MGUS. The authors propose that ploidy status
and immunoglobulin heavy chain rearrangements were early events delineating different
pathogenic pathways [50]. The study revealed a significantly lower frequency of delta 13 in
the pre-malignant conditions than in MM. Delta 13 was rare in MGUS (25%) and SMM (34%)
compared to MM (47%).Translocations directly involve cyclin D genes (CCND1 and CCND3)
suggesting a possible role of delta 13 in the progression of the disease, specifically in these
genetic sub-groups [50]. In MGUS, the greatest variation in the proportion of abnormal plasma
cells carrying the abnormality was seen for delta 13 and 16q23 deletion. The presence and time
of occurrence of delta 13 depend on the presence of specific concurrent abnormalities: earlier
Translocation
(Prevalence %) [References]
Group Deregulated Gene Cell Level Consequence
IgH translocated MGUS
(50%) [50]
t(11;14)(q13;q32)
(15%-25% of MGUS/SMM patients)
[50-53]
D group cyclin
Directly
CCND1 Enhance cyclin D1
(normally B-cells express
cyclin D2 and cyclin D3 but
not cyclin D1)
t(6;14)(p21;q32)
(1% of MGUS/SMM patients) [50]
D group cyclin
Directly
CCND3 Enhance cyclin D3
t(4;14)(p16;q32)
(2%-5% of MGUS patients)
(13% of SMM patients) [48, 52-54]
D group cyclin
Indirectly
FGFR-3 and MMSET Enhance cyclin D2
t(14;16)(q32;q23)
(3%-5% of MGUS/SMM patients) [53, 55]
MAF translocation
group
c-MAF upregulation Enhance cyclin D2
t(14;20)(q32;q11)
(5% of MGUS patients)
(0%-1.5% of SMM patients) [50, 55]
MAF translocation
group
MAFB upregulation Enhance cyclin D2
MGUS: Monoclonal gammopathy of undetermined significance; SMM: Smoldering multiple myeloma
Table 2. Translocations into the immunoglobulin heavy chain locus in MGUS and SMM patients
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when t(4;14) or t(14;16) was present, later with t(14;20), and even later with t(11;14) or
t(6;14).This data suggests a possible role of delta 13 in the transition from MGUS to MM
specifically in cases with t(11;14) or t(6;14). Chromosome 13 deletion on its own probably does
not affect prognosis [50].
We have treated previously in this chapter, that MGUS progresses to MM at annual frequency
of 1% [2], however little is known about the proportion of patients whose MM has evolved
from this precursor condition. Zhan F et al [56] developed a gene-expression profiling study
in which 52 genes differentially expressed in MGUS and MM identifying and validating a
MGUS-like MM with favorable clinical features and longer survival.
Point mutations, such as N-RAS, K-RAS, MYC up-regulation, and gain or loss of chromosome
1q or 1p, also seem to correlate with disease progression from myeloma precursor disease,
MGUS and SMM [57]. Rasmussen et al [58] found a high prevalence of activating RAS
mutations in MM (31%) compared with MGUS (5%) and suggest that these mutations may
facilitate the transition from MGUS to MM in a subset of patients. Only N-RAS mutation was
found in MGUS. At present, RAS mutations are the major genetic difference between MGUS
and MM [43].
In a case report, Chiecchio et al [59] describe the clinicopathological and genetic findings of a
young patient initially diagnosed with SMM: loss of 1p and a rearrangement of MYC were
first observed in a small population of plasma cells one year prior to the clinical diagnosis of
MM, but these subclones increased rapidly in size to become the major population suggesting
that they were directly involved in the transformation [59].
MicroRNA is a novel class of short non-coding RNA molecules regulating a wide range of
cellular functions through translational repression of their target genes. Recently, epigenetic
dysregulation of tumor-suppressor microRNA genes by promoter DNA methylation has been
implicated in human cancers, including MM [60]. It has been reported that MGUS and MM
patients seem to upregulate miR-21, miR-106b, miR-181a, and miR-181b; which are microRNA
involved in B-cell and T-cell lymphocyte differentiation as well as oncogene regulation [61].
Recently, Jones et al [62] have developed a biomarker signature using microRNAs extracted
from serum, which has potential as a diagnostic and prognostic tool for MM. The combination
of miR-1246 and miR-1308 can distinguish MGUS from myeloma patients [62].
In the progression process to malignant condition it also seems to be important the proportion
of clonal plasma cell with specific genetic abnormalities in every diagnostic group. In fact,
López-Corral et al [63] observed a significant difference in MGUS compared with SMM, and
in SMM compared with MM, suggesting that the progression from MGUS to SMM and
eventually to MM involves a clonal expansion of genetically abnormal plasma cell. This result
was found for immunoglobulin heavy chain translocations, 13q and 17p deletions, and 1q
gains. In other recent study, López-Corral et al [49] analyzed the genomic characteristics by
FISH, Single-nucleotide polymorphism arrays and gene expression profile finding that the
overexpression of four SNORD genes (SNORD25, SNORD27, SNORD30 and SNORD31) was
correlated with shorter time progression to symptomatic MM. However, they failed to find
chromosomal lesions associated to risk of progression, observing an increase in the proportion
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of clonal plasma cells carrying a given abnormality supporting the hypothesis that the number
of genetically abnormal plasma cell increases from high-risk SMM to active MM [49]. In a later
study López-Corral et al [64] have performed for the first time a comprehensive high-resolu‐
tion analysis of genomic imbalances by high-density 6.0 S SNP-array in 20 MGUS, 20 SMM
and 34 MM patients to search for the genetic lesions that may be involved in the transformation
from MGUS to MM. Their results showed a progressive increase in the incidence of copy
number abnormalities from MGUS to SMM and to MM. The study shows for the first time the
different copy number and loss of heterozygosity profiles present at three stages of monoclonal
gammopathy evolution: MGUS, SMM and MM. There were significantly more copy number
alterations in MM than in MGUS patients, values for SMM being intermediate [64].
Taking into account that the majority of MM plasma cell are quiescent, it has been suggested
that the growth of the tumor is restricted to a specialized subpopulation of cells [43]. In this
sense, the bone marrow microenvironment plays an essential role in the pathogenesis of MM.
The bone marrow microenvironment in which MGUS and MM cells live is composed of
extracellular matrix and different types of cells, e.g., stromal cells, osteoclasts, osteoblasts,
immune cells (T lymphocytes, dendritic cells), other hematopoietic, cells and their precursors,
and vascular endothelial cells. Reciprocal positive and negative interactions among these cells
are mediated by a variety of adhesion molecules, cytokines, and receptors [65]. MAF translo‐
cations dysregulate expression of a MAF transcription factor that causes increased expression
of many genes, including CCND2 and adhesion molecules that are thought to enhance the
ability of the tumor cell to interact with the bone marrow microenvironment [66].
In summary, it has been proposed that the pathogenesis of MGUS and MM can be considered
as occurring in three phases [6]. First, partially overlapping genetic events common to MGUS
and MM include at a minimum primary immunoglobulin heavy chain translocations, hyper‐
diploidy, and del13 that lead directly or indirectly to dysregulation of a CCND gene; second,
the transition from MGUS to MM is associated with increased MYC expression and sometimes
K-RAS mutations, but can also include del13 in t(11;14) tumors; third, additional progression
of the MM tumor seems to be associated with other events. For example, increased proliferation
and genomic instability, and decreased dependence on the bone marrow microenvironment,
sometimes including extramedullary spread of disease, can be associated with late MYC
rearrangements that often involve an immunoglobulin locus, activating mutations of the
nuclear factor-κB pathway, deletion or mutation of TP53, and inactivation of p18INK4c or RB
[65] (see Fig. 1).
6. Clinical management
As mentioned above, the UK Myeloma Forum and the Nordic Myeloma Study Group have
proposed guidelines for the management of MGUS [28]. They suggest that is essential that
patients should be monitored not only by laboratory testing but also clinically. Low risk
patients (serum IgG <1.5 g/dL; IgA or IgM <1.0 g/dL; normal free light chain ratio in the absence
of symptoms such as anemia or renal dysfunction) can be monitored in the primary-care setting
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at intervals of 3-4 months initially for the first year and then lengthened to 6-12 months based
on the patient`s clinical history, laboratory results and comorbid conditions. Should be checked
for serum protein electrophoresis, complete blood count, calcium, and serum creatinine every
6 months and if they are stable, every 2 to 6 years. There is also an alternative strategy
suggesting that screening should be performed only if there is an increase in symptoms
associated with MM. International Myeloma Working Group members suggest that the
patients with low risk-MGUS should be followed during 6 months after the diagnosis of MGUS
[32]. On the other hand, they specified that a bone marrow examination should be required if
the patients had any CRAB features.
UK  Myeloma  Forum  and  the  Nordic  Myeloma  Study  Group  recommend  that  patients
with  high-risk  MGUS  (IgG  ≥1.5  g/dL;  IgA  or  IgM  >1.0  g/dL;  IgD  or  IgE  at  any  level)
should be referred to a hematology specialist 3-4 times per year as a minimum [28]. The
Figure 1. Model for molecular pathogenesis of monoclonal gammopathy of undetermined significance (MGUS) and
multiple myeloma (MM). TR1, the initial transition to a recognizable tumor involves two mostly non-overlapping path‐
ways (IgH translocations versus multiple trisomies) that include primary events associated with dysregulated cyclin D
expression in MGUS and MM. TR2, the transition from MGUS to MM is associated with increase MYC expression and
sometimes with activating mutations of K-RAS or chromosome 13 deletion. Early and late progression events for
symptomatic MM tumors are shown. Reproduced with permission from Kuehl WM and Bergsagel PL. Molecular
pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 2012;122(10):3456-63. doi:10.1172/
JCI61188. Copyright from the American Society for Clinical Investigation.
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recommended tests for monitoring include serum protein electrophoresis, serum total im‐
munoglobulin, complete blood count, creatinine, urea, electrolytes and serum calcium. In
addition,  it  should  be  evaluated  using  bone  marrow  cytogenetic  and  FISH  with  bone
imaging studies. Nevertheless, it is important to highlight that sometimes it will be neces‐
sary to perform Magnetic Resonance Imaging or Positron Emission Tomography-Comput‐
ed  Tomography,  instead  of  traditional  x-rays.  Patients  with  unexplained  anemia  or
kidney  failure  should  be  evaluated  with  a  full  bone  scan  that  also  include  cytogenetic
and FISH. Korde et al [57] reported that is critical to recognize that in a disease such as
MM, where defining criteria rely on the presence or absence of end-organ damage, diag‐
nosis is  only as good as the tools and technology able to detect end-organ damage. For
instance, in SMM or high-risk MGUS patients suspicious to harbor bone disease, imaging
evaluation  may  be  better  served  by  obtaining  magnetic  resonance  imaging  or  Positron
Emission  Tomography-Computed  Tomography  rather  than  traditional  skeletal  surveys.
International  Myeloma  Working  Group  members  recommend  for  intermediate-risk  and
high-risk MGUS patients should have a bone marrow aspirate and biopsy with both con‐
ventional  cytogenetics  and  FISH  [32].  If  available,  a  plasma  cell  labeling  index  and  a
search for circulating plasma cells in the peripheral blood using flow cytometry are use‐
ful.  Patients with IgM isotype should have a computational tomography scan of the ab‐
domen  since  asymptomatic  retroperitoneal  lymph  nodes  may  be  present.  If  there  is
evidence  of  MM or  Waldeström macroglobulinemia,  lactate  dehydrogenase,  2-microglo‐
bulin,  and C-reactive protein levels should be measured. If  the results of  these tests are
satisfactory,  International  Myeloma Working  Group recommend patients  should  be  fol‐
lowed with serum protein electrophoresis and complete blood cell count in 6 months and
then annually for life [32].
7. Management
In clinical practice, patients with MGUS are followed clinically without treatment until
progression. However, the existence of easily identifiable precursor states represents an
opportunity for chemoprevention [67]. However, it must be weighed that benefits achieved
by treating a precursor state is greater than a potential for therapeutic toxicity. Recently, Korde
et al [57] revised early treatment strategies for MGUS and SMM.
Bhattacharyya et al [68] reported a clinic case of IgM-MGUS associated with cryoglobulinemia
and cold agglutinin disease, which was treated with immunotherapy and was successful
(Table 3). Immunochemotherapy, consisting of rituximab (375 mg/m2, day 1), fludarabine (25
mg/m2, days 2-4), and cyclophosphamide (250 mg/m2, days 2-4), was administered every 4
weeks up to three times as a first-line treatment followed by three cycles of monthly rituximab
treatment. Extensive skin lesions with livedo reticularis entirely disappeared prior to initiation
of the second cycle in association with the declined serum level of IgM.
Pepe et al [69] studied 100 patients affected by MGUS, grouped according to the presence
(group A, 50 patients) or absence (group B) of vertebral fractures and/or osteoporosis. Group
A was treated with alendronate  (70  mg/weekly)  plus  calcium and cholecalciferol  for  18
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months, and group B was treated with calcium and cholecalciferol. Treatment with alendro‐
nate could lead to a significant reduction in fracture risk in MGUS patients with skeletal
fragility. During the whole period of investigation, eight patients in group A developed MM
and therefore were not able to continue the study. A further 12 patients included in group
A did not want to take the drugs prescribed. Additionally, the author indicated that this
study has some limitations, mainly because of the lack of a real control group (longitudinal‐
ly followed for the entire observation period) and the lack of morphometric evaluation of
vertebral fractures at 18 months. Another similar study was administered zoledronic acid to
Drug [References] Treatment
scheme
Nº of patients (age or
study/control)
Benefit Observations
Zoledronic acid [70] 4 mg, i.v. at 0, 6,
and 12 months
54 MGUS
and osteopenia or
osteoporosis
(50-91 years;
median=67 years)
Reducing fractures. 48 patients completed the
study.
Some patients showed
adverse effects. Progression
of MGUS does not diminish
with time.
Alendronate plus
calcium and
cholecalciferol
vs.
calcium and
cholecalciferol [69]
70 mg/weekly, at
18 months
100 MGUS
With presence or
absence (control)
vertebral fractures
and/or osteoporosis
(50/50)
Reducing fractures. 8 patients developed MM
12 patients did not want to
take the drugs.
Rituximab,
fludarabine, and
cyclophosphamide
[68]
Every 4 weeks up
to three times
followed by three
cycles of monthly
rituximab
treatment
1 MGUS
associated with
cryoglobulinemia and
cold agglutinin disease
Decreases M-protein
and skin lesions
disappeared.
NA
Curcumin
vs.
placebo [73]
4 g/day oral 26 MGUS
(17/9)
Decreases bone
resorption and M-
protein (12-30%) of
patients with M-protein
>20 g/L
NA
Curcumin
vs.
placebo [74]
4 g/day and an
open-label 8 g
curcumin extension
study, oral, at 3
months
19 MGUS
17 SMM
(12/13)
Decreasing free light
chain and marker of
bone resorption.
Curcumin may benefit some
but not all patients with
MGUS and SMM.
MGUS: Monoclonal gammopathy of undetermined significance; SMM: Smoldering multiple myeloma; NA: Not
available.
Table 3. Therapy on patients with MGUS
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54 patients with MGUS and osteopenia or osteoporosis [70]. They also demonstrated that
increase bone mineral density in patients with bone loss with the theoretical added benefit
of reducing fractures although it was not observed that the progression can be delayed or
prevented.
There are two ongoing studies, in the first, the aim is to assess whether omega-3 fatty acids
reduce activated NF-κB levels in peripheral blood lymphocytes [71]. Omega-3 supplementa‐
tion will be initiated at three 1250 mg capsules daily for the first month. If dose is well tolerated,
it will be increased to six 1250 mg capsules daily for 30 days and finally to nine 1250 mg capsules
daily. Treatment period is 12 months (study design nonrandomized). No study results posted
on clinicaltrials.gov [71]. In the second study, the aim is to test whether green tea extract
reduces the M-protein concentration [72]. Patients receive oral green tea catechin extract
(Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the
absence of disease progression or unacceptable toxicity. No study results posted on clinical‐
trials.gov [72].
Golombick et al [73] investigated the effect of curcumin on plasma cells and osteoclasts in
patients with MGUS (see Table 3). Twenty-six patients with MGUS were randomized into
two groups (single-blind, randomized, crossover pilot). The pilot study found that curcu‐
min may decrease both serum M-protein (in patients with levels of >20 g/L) and urinary N-
telopeptide  of  type  I  collagen  bone  turnover  marker  in  patients  with  MGUS.  Recently,
Golombick et al [74] performed a randomized, double-blind placebo-controlled crossover 4
g curcumin study and an open-label extension study using an 8 g curcumin. 19 MGUS and
17 SMM were randomized into two groups: one received 4 g curcumin and the other 4 g
placebo, crossing over at 3 months. 25 patients completed the 4 g crossover study and 18 the
8 g extension study. In some patients curcumin therapy decreased the free light-chain ratio
and uDPYD (a marker of bone resorption).
Curcumin is the most active component in Curcuma longa or turmeric (tropical plant native to
southern and southeastern tropical Asia). Curcumin has been shown to downregulate IL-6 and
nuclear factor-κB; to inhibit osteoclastogenesis and to reduce bone turnover; suppresses
proliferation and induces apoptosis in MM cells [75] and inhibits osteoclastogenesis through
the suppression of RANKL signaling [76]. Nevertheless, it is known that curcumin inhibits
IL-12 production in dendritic cells, thereby dampening the Th1 response [77]. This suggests
that may have an immunosuppressive effect. However, Rajkumar [78] indicated that finding
reported by Golombick [74] is a modest decrease in free light chain levels by 25-50% in one
quarter of the patients, reason why he disagrees with curcumin as a preventive or therapeutic
strategy in MGUS (Table 3). Rajkumar also indicated that using risk stratification model
approximately 50% of all MGUS patients are considered low-risk MGUS, and have a lifetime
risk of progression of only 2%. Therefore, he recommends that focus should be put on
preventive strategies in patients with high-risk SMM.
There is an increased interest in identifying biomarkers that can predict patients who will
inevitably progress to symptomatic MM. These include genetic and/or epigenetic targets and
microenvironment and/or its interaction with tumor cells, which may change the future of
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disease progression [65]. Dynamic changes in tumor and microenvironment, cell immunophe‐
notype, mRNA and protein expression, should offer insight into disease progression [57, 78].
8. Conclusion
In conclusion, it is crucial to follow up cases of MGUS carefully, including their systematic
recording as a fundamental contribution to understand the evolution of this pathology and its
malignant transformation process. This will be critical to develop better biomarkers that
contribute to understand the evolution and malignant transformation of MGUS. These efforts
should lead to the development of new, more effective management and treatment strategies.
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SMM Smoldering multiple myeloma
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